Affinity DataIC50: 3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 34nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 36nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 39nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 51nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 52nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 52nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 53nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 81nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 90nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 92nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 95nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 100nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 160nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 540nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 900nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 1.53E+3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 1.64E+3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 2.32E+3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 3.20E+3nMAssay Description:Inhibition of LMIK1 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 3.20E+3nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: 5.60E+3nMAssay Description:Inhibition of Abl (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 1.09E+4nMAssay Description:Inhibition of LCK (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2.41E+4nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: >2.70E+4nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: >2.70E+4nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: >2.70E+4nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: >2.70E+4nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: >2.70E+4nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
Affinity DataIC50: >2.70E+4nMAssay Description:Inhibition of human full-length LIMK2 expressed in Sf9 cells assessed as incorporation of [33P] from ATP into biotinylated-cofilin substrate in prese...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase kinase 5(Homo sapiens (Human))
Lexicon Pharmaceuticals
Curated by ChEMBL
Lexicon Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of MAP4K5 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CDK1 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CDK2 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of GSK3beta (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Homo sapiens (Human))
Lexicon Pharmaceuticals
Curated by ChEMBL
Lexicon Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CHK2 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of Jak2 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of Jak3 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1(Homo sapiens (Human))
Lexicon Pharmaceuticals
Curated by ChEMBL
Lexicon Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of Flt1 (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of Fgr (unknown origin) in presence of 1 mM ATPMore data for this Ligand-Target Pair